| Title : Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl methyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models - Thomas_2009_J.Pharmacol.Exp.Ther_328_556 |
| Author(s) : Thomas L , Tadayyon M , Mark M |
| Ref : Journal of Pharmacology & Experimental Therapeutics , 328 :556 , 2009 |
| Abstract : |
| PubMedSearch : Thomas_2009_J.Pharmacol.Exp.Ther_328_556 |
| PubMedID: 18971371 |
| Title : (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors - Thomas_2008_J.Pharmacol.Exp.Ther_325_175 |
| Author(s) : Thomas L , Eckhardt M , Langkopf E , Tadayyon M , Himmelsbach F , Mark M |
| Ref : Journal of Pharmacology & Experimental Therapeutics , 325 :175 , 2008 |
| Abstract : |
| PubMedSearch : Thomas_2008_J.Pharmacol.Exp.Ther_325_175 |
| PubMedID: 18223196 |
| Title : 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes - Eckhardt_2007_J.Med.Chem_50_6450 |
| Author(s) : Eckhardt M , Langkopf E , Mark M , Tadayyon M , Thomas L , Nar H , Pfrengle W , Guth B , Lotz R , Sieger P , Fuchs H , Himmelsbach F |
| Ref : Journal of Medicinal Chemistry , 50 :6450 , 2007 |
| Abstract : |
| PubMedSearch : Eckhardt_2007_J.Med.Chem_50_6450 |
| PubMedID: 18052023 |
| Gene_locus related to this paper: human-DPP4 |